Ancestim

Ancestim
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	s.c. injection only, premedication with H1 and H2 antihistamines and beta-receptor agonists for bronchodilation
ATC code	L03AA12 (WHO) ;
Pharmacokinetic data
Elimination half-life	2.5 h
Excretion	renal: 90%
Identifiers
CAS Number	163545-26-4 ;
ChemSpider	none;
UNII	PYB4Q6JG41;
KEGG	D02937 ;
	(what is this?) (verify)

Ancestim is a recombinant methionyl human stem cell factor, branded by Amgen as StemGen. It was developed by Amgen and sold to Biovitrium, now Swedish Orphan Biovitrum, in December, 2008.^[1]

It is a 166 amino acid protein produced by E. coli bacteria into which a gene has been inserted for soluble human stem cell factor.^[2] It has a monomeric molecular weight of approximately 18,500 daltons and normally exists as a noncovalently associated dimer. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis, except for the addition of an N-terminal methionine retained after expression in E. coli. Because Ancestim is produced in E. coli, it is nonglycosylated. Ancestim is supplied as a sterile, white, preservative-free, lyophilised powder for reconstitution and administration as a subcutaneous (SC) injection and is indicated for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells for later transplantation in certain cancer patients.^[3]

References

↑ Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived July 3, 2012, at the Wayback Machine
↑ da Silva MG, Pimentel P, Carvalhais A, et al. (2004). "Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection". Bone Marrow Transplant. 34 (8): 683–91. doi:10.1038/sj.bmt.1704602. PMID 15322567.
↑ "{{Webarchive|url=https://web.archive.org/web/20131230232434/http://www.sobi.com/en/Healthcare-Professionals/Products-alphabetical-list/Stemgen/ |date=2013-12-30 }} Sobi's StemGen page". Archived from the original on 2016-07-29. Retrieved 2013-12-30.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[BiovitriumDeal-1] Amgen press office. Biovitrum Closes Product Acquisition Deal with Amgen Archived July 3, 2012, at the Wayback Machine

[pmid15322567-2] Silva MG, Pimentel P, Carvalhais A, et al. (2004). "Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection". Bone Marrow Transplant. 34 (8): 683–91. doi:10.1038/sj.bmt.1704602. PMID 15322567.

[3] "{{Webarchive|url=https://web.archive.org/web/20131230232434/http://www.sobi.com/en/Healthcare-Professionals/Products-alphabetical-list/Stemgen/ |date=2013-12-30 }} Sobi's StemGen page". Archived from the original on 2016-07-29. Retrieved 2013-12-30.

[1]

[2]

[3]